Clinical trial
A Phase II Study of Induction Tucatinib and Trastuzumab With Total Neoadjuvant Therapy for Locally Advanced HER2-amplified Rectal Adenocarcinoma
NCT05672524 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Induction Tucatinib and Trastuzumab With Total Neoadjuvant Therapy for Locally Advanced HER2-amplified Rectal Adenocarcinoma
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 30, 2022
- Completion date
- July 31, 2030
- Enrollment
- 37 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
adenocarcinoma of the rectum, her2 positive rectal adenocarcinoma, locally advanced rectal adenocarcinoma, rectal adenocarcinoma, rectal cancer